Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Financing

Kyntra Bio drops prostate cancer pair, trims royalty-deal exposure by $60m, pivots to MDS

With its third-quarter results, the US biotech narrows its pipeline to roxadustat in myelodysplastic syndromes, with a Phase 3 start that still needs outside money.

16 Nov 2026 · Kyntra Bio, Inc. KYNB · Company news

Kyntra Bio, Inc. has ended its work in metastatic castration-resistant prostate cancer and is staking its near-term plans on a single programme: roxadustat for anaemia in myelodysplastic syndromes (MDS). The company set out the change on 16 November 2026 alongside its third-quarter figures.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Kyntra Bio, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →